Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

A Single Dose Of Compound SB-681323 Compared To Prednisolone On A Protein That Is an Indicator For Rheumatoid Arthritis

27 juli 2017 bijgewerkt door: GlaxoSmithKline

A Randomised, Placebo-controlled, Parallel Group Single Dose Study of SB681323 in Patients With Active RA to Investigate the CRP Dose Response Relationship

This study is designed to compare a range of doses of SB-681323 with prednisolone, which has known effects on rheumatoid arthritis patients. By comparing the two drugs and their effects on blood proteins that indicate for rheumatoid arthritis, we hope to ascertain information on the most effective dose of SB-681323 to use in future.

Studie Overzicht

Toestand

Voltooid

Conditie

Interventie / Behandeling

Studietype

Ingrijpend

Inschrijving (Werkelijk)

77

Fase

  • Fase 2

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studie Locaties

  • Australië
    • New South Wales
      • Darlinghurst, New South Wales, Australië, 2010
        • GSK Investigational Site
    • Queensland
      • Douglas, Queensland, Australië, 4814
        • GSK Investigational Site
      • Woolloongabba, Queensland, Australië, 4102
        • GSK Investigational Site
    • South Australia
      • Daw Park, South Australia, Australië, 5041
        • GSK Investigational Site
      • Woodville, South Australia, Australië, 5011
        • GSK Investigational Site
    • Tasmania
      • Hobart, Tasmania, Australië, 7000
        • GSK Investigational Site
    • Western Australia
      • Shenton Park, Western Australia, Australië, 6008
        • GSK Investigational Site
  • Duitsland
      • Berlin, Duitsland, 14059
        • GSK Investigational Site
      • Berlin, Duitsland, 13125
        • GSK Investigational Site
      • Berlin, Duitsland, 14109
        • GSK Investigational Site
      • Berlin, Duitsland, 12163
        • GSK Investigational Site
    • Baden-Wuerttemberg
      • Villingen-Schwenningen, Baden-Wuerttemberg, Duitsland, 78054
        • GSK Investigational Site
    • Niedersachsen
      • Hildesheim, Niedersachsen, Duitsland, 31134
        • GSK Investigational Site
    • Sachsen
      • Chemnitz, Sachsen, Duitsland, 09111
        • GSK Investigational Site
      • Leipzig, Sachsen, Duitsland, 04107
        • GSK Investigational Site
      • Leipzig, Sachsen, Duitsland, 04229
        • GSK Investigational Site
  • Frankrijk
      • Montpellier Cedex 5, Frankrijk, 34295
        • GSK Investigational Site
    • Picardie
      • Amiens, Picardie, Frankrijk, 80054
        • GSK Investigational Site
  • Russische Federatie
      • Ekaterinburg, Russische Federatie, 620102
        • GSK Investigational Site
      • Moscow, Russische Federatie, 115522
        • GSK Investigational Site
      • Ryazan, Russische Federatie, 390026
        • GSK Investigational Site
      • Yaroslavl, Russische Federatie, 150003
        • GSK Investigational Site
  • Verenigd Koninkrijk
      • Oxford, Verenigd Koninkrijk, OX3 7LP
        • GSK Investigational Site
      • Sheffield, Verenigd Koninkrijk, S10 2RX
        • GSK Investigational Site
    • Cambridgeshire
      • Cambridge, Cambridgeshire, Verenigd Koninkrijk, CB2 0QQ
        • GSK Investigational Site
    • Lancashire
      • Wigan, Lancashire, Verenigd Koninkrijk, WN6 9EP
        • GSK Investigational Site
    • Merseyside
      • Liverpool, Merseyside, Verenigd Koninkrijk, L9 7AL
        • GSK Investigational Site
    • Northumberland
      • Newcastle, Northumberland, Verenigd Koninkrijk, NE1 4LP
        • GSK Investigational Site

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

18 jaar en ouder (Volwassen, Oudere volwassene)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Allemaal

Beschrijving

Inclusion criteria:

  • Must have a diagnosis of RA according to the revised 1987 criteria of the American College of Rheumatology.
  • Must have 3 or more swollen or 3 or more tender/painful joints at screening.
  • Must be on stable weekly methotrexate (2.5mg - 25mg) for at least eight weeks prior to screening.

Exclusion criteria:

  • Must not be morbidly obese.

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Behandeling
  • Toewijzing: Gerandomiseerd
  • Interventioneel model: Parallelle opdracht
  • Masker: Dubbele

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Analysis for C-Reactive protein (CRP) levels 72 hours post-dose following SB-681323
Tijdsspanne: Day 3 (at 72 hour)
CRP levels were compared between SB-681323 and placebo 72 hours post-dose. The ratio of the dose response relationship of placebo and 7.5mg, 15mg and 25mg of SB-681323 has been presented.
Day 3 (at 72 hour)

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Analysis of CRP levels 24 and 48 hours post-dose following SB-681323
Tijdsspanne: Day 1 (at 24 hour) and Day 2 (at 48 hour)
CRP levels were compared between SB-681323 and placebo 24 and 48 hours post-dose. The ratio of the dose response relationship of placebo and 7.5mg, 15mg and 25mg of SB-681323 has been presented.
Day 1 (at 24 hour) and Day 2 (at 48 hour)
Analysis of Interleukin (IL)-6 levels up to 72 hours post-dose following SB-681323
Tijdsspanne: Upto Day 3 (at 1, 3, 24 and 72 hour)
A blood sample of approximately 5 milliliter (mL) was taken for measurement of serum markers. IL-6 measurements were performed at 1 hour, 3, hours, 24 hours and 72 hours post-dose. The ratio of the dose response relationship of placebo and 7.5mg, 15mg and 25mg of SB-681323 has been presented.
Upto Day 3 (at 1, 3, 24 and 72 hour)
Number of participants with adverse events (AE) and serious adverse events (SAE)
Tijdsspanne: Upto Day 3 (72 hours)
An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, may jeopardize the participant or require medical or surgical intervention to prevent one of the other outcomes listed in the definition above, or is an event of possible drug-induced liver injury. There were no SAEs reported in this study.
Upto Day 3 (72 hours)
Change from Baseline in vital sign systolic blood pressure (SBP) and diastolic blood pressure (DBP)
Tijdsspanne: Baseline (at pre-dose Day 0) and Day 3 (at 90 minutes, 3 hour, 24 and 72 hour)
Supine vital signs SBP and DBP were recorded whilst the participant was in a supine position (participant lying flat with maximum one pillow) having rested in that position for at least 10 minutes before each reading. Measurements were performed at 90 minutes, 3 hours, 24 hours and 72 hours post-dose. Baseline was defined as assessment performed pre-dose at Day 0. Change from Baseline was calculated by subtracting the Baseline value from the individual post-randomization values at the time of assessment.
Baseline (at pre-dose Day 0) and Day 3 (at 90 minutes, 3 hour, 24 and 72 hour)
Change from Baseline in vital sign heart rate
Tijdsspanne: Baseline (at pre-dose Day 0) and Day 3 (at 90 minutes, 3 hour, 24 and 72 hour)
Supine vital signs (heart rate) was recorded whilst the participant was in a supine position (participant lying flat with maximum one pillow) having rested in that position for at least 10 minutes before each reading. Measurements were performed at 90 minutes, 3 hours, 24 hours and 72 hours post-dose. Baseline was defined as assessment performed pre-dose at Day 0. Change from Baseline was calculated by subtracting the Baseline value from the individual post-randomization values at the time of assessment.
Baseline (at pre-dose Day 0) and Day 3 (at 90 minutes, 3 hour, 24 and 72 hour)
Number of participants with abnormal electrocardiogram (ECG) findings
Tijdsspanne: Day 1 (pre-dose, 1 hour and 3 hour)
Full 12-lead ECGs were recorded using an ECG machine that automatically calculated the pulse rate and measured PR, RR, QRS, QT, QTc(b) intervals (Bazett's correction was applied to QTc measurements). Measurements were carried out at pre-dose, 1 hour and 3 hours on Day 1. ECG findings were characterized as abnormal-not clinically significant (A-NCS) and abnormal-clinically significant (A-CS). Data has been presented for A-NCS findings on Day 1.
Day 1 (pre-dose, 1 hour and 3 hour)
Number of participants with clinical chemistry data outside the clinical concern range
Tijdsspanne: Upto Day 3 (pre-dose, 24, 48 and 72 hours
Clinical chemistry parameters included albumin, alkaline phosphatase, alanine amino transferase, indirect bilirubin, calcium, chloride, creatinine, gamma glutamyl transferase, glucose, potassium, lactate dehydrogenase, triglycerides. Measurements were carried out at pre-dose, 24 hours, 48 hours and 72 hours. Data for number of participants with values outside clinical concern range defined as high and low have been presented.
Upto Day 3 (pre-dose, 24, 48 and 72 hours
Number of participants with hematology data outside the clinical concern
Tijdsspanne: Upto Day 3 (pre-dose, 24 and 72 hours)
Hematology parameters included eosinophils, hemoglobin, hematocrit, lymphocytes, mean corpuscle hemoglobin, mean corpuscle volume, platelet count, reticulocytes, white blood cell count (WBC). Measurements were carried out at pre-dose, 24 hours and 72 hours. Data for number of participants with values outside clinical concern range defined as high and low have been presented.
Upto Day 3 (pre-dose, 24 and 72 hours)
Number of participants with abnormal urinalysis dipstick results
Tijdsspanne: Upto Day 3 (pre-dose, 24 and 72 hours)
Approximately 10-20 mL mid-stream urine was collected into a sterile container and was screened by dipstick for: occult blood, proteins, ketones, glucose, red blood cells (RBC) and WBC. Sediment microscopy was performed only if any of the Multi-stick tests were abnormal. In such cases, microscopy was performed for: WBC, RBC, hyaline casts, granular casts, cellular casts. Data for number of participants with abnormal urinalysis results for positive parameters as assessed by dipstick and microscopic analysis have been presented.
Upto Day 3 (pre-dose, 24 and 72 hours)
Whole blood messenger RNA (mRNA) levels of tumor necrosis factor alpha [TNF-α], IL-8, IL-1β and Cyclo-oxygenase-2 [COX-2] (and other genes implicated in the pathogenesis of RA or genes involved in the mode of action of the compounds administered)
Tijdsspanne: Pre-dose, 45 minutes, 90 minutes and 3 hours on Day 1
Blood samples were taken for extraction of whole blood mRNA (2 x 2.5mL PAXgene tubes). The samples were taken at the time-points pre-dose, 45 minutes, 90 minutes and 3 hours. Messenger RNA levels for various markers was measured. These markers included Prednisolone markers: DDIT4, DUSP1, FKBP5, GILZ, IL1R2, TXNIP, ZNF145 and p38 markers: COX2, IFI30, IL1b, IL6, IL8, TNF. An aliquot of mRNA was stored for later analysis of other genes associated with the pathogenesis of RA and in the mode of action of the compounds administered.
Pre-dose, 45 minutes, 90 minutes and 3 hours on Day 1

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Sponsor

GlaxoSmithKline

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

21 juni 2005

Primaire voltooiing (Werkelijk)

3 augustus 2006

Studie voltooiing (Werkelijk)

3 augustus 2006

Studieregistratiedata

Eerst ingediend

24 augustus 2005

Eerst ingediend dat voldeed aan de QC-criteria

24 augustus 2005

Eerst geplaatst (Schatting)

25 augustus 2005

Updates van studierecords

Laatste update geplaatst (Werkelijk)

31 juli 2017

Laatste update ingediend die voldeed aan QC-criteria

27 juli 2017

Laatst geverifieerd

1 juli 2017

Meer informatie

Termen gerelateerd aan deze studie

Trefwoorden

Aanvullende relevante MeSH-voorwaarden

Andere studie-ID-nummers

  • RA1104046

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Klinische onderzoeken op Artritis, reumatoïde

Klinische onderzoeken op Prednisolon

Zoek naar vergelijkbare onderzoeken

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

CROs by country

CROs in Romania

Voorwaarden

Zeldzame ziekten

Geneesmiddelinterventies

Voedingssupplementen

Sponsor / medewerkers

Locaties

3
Abonneren